Press Releases

Grant of share options to senior management

By April 22, 2016No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 3,261,577 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”).

Pete A. Meyers, Chief Financial Officer, has been granted 2,961,577 options to purchase Ordinary Shares which vest over a four year period and are partially based on meeting certain performance targets. Rajesh B. Shukla Ph.D., Vice President of Clinical Operations, was granted 300,000 options to purchase Ordinary Shares which vest over a four year period. The options have an exercise price of 40.50 pence per Ordinary Share, being the closing price of the Ordinary Shares on 21 April 2016, the date of grant of the options.

ENQUIRIES

Motif Bio plc

Graham Lumsden, Chief Executive Officer
info@motifbio.com

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners Limited (Broker)

Patrick Claridge / David Hignell
John Howes / Rob Rees (Broking)
+44 (0) 207 382 1100

Walbrook PR Ltd. (Public and Investor Relations)

Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
motifbio@walbrookpr.com

MC Services AG (European IR)

Raimund Gabriel
+49 (0) 89 210 2280

Notes to Editors

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus).  Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.